Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
Joint discovery and development of novel small molecule therapies for cancer
Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new cancer therapies.
The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos will be responsible for the discovery and development of new candidate drugs against these targets. Servier will have an exclusive option to license each small molecule program after the completion of pre-clinical development by Galapagos. Upon exercise of each option, Servier will be responsible for further clinical development, registration and commercialization. Galapagos retains exclusive rights for clinical development, registration and commercialization in the United States.
Under the terms of the agreement, Galapagos will receive research access payments of €2 million from Servier. Galapagos is also eligible to receive discovery, development, regulatory and other milestone payments that could reach €260 million, plus royalties upon commercialization of products by Servier.
Other news from the department business & finance
